Document resource
Background and Importance Atogepant is a recently approved oral calcitonin gene-related peptide antagonist for migraine prophylaxis in adults. Real-world data on its efficacy and safety remain limited.Aim and Objectives The objective of this study is to assess the effectiveness and safety of atogepant in real-world clinical practice.Material and Methods A retrospective observational study was conducted on migraine patients who received atogepant between August 2024 and June 2025, with at least 3 months of treatment. Demographic and clinical data were collected. Treatment efficacy was measured by the reduction in monthly migraine days. To analyse atogepant’s safety, adverse events related to this drug were recorded.Patients were classified as non-responders (<30% reduction in monthly migraine days), partial responders (30–50% reduction) or good responders (>50% reduction).Results 44 patients were included in the study: 100% female; mean age 46,5±11,1 years; 40 (90,9%) with diagnosis of chronic migraine and 4(9,1%) with episodic migraine. 21 (47,7%) patients had been previously treated with monoclonal antibodies.At treatment initiation, the median monthly migraine days was 13 (9,5–17), and the median monthly headache days was 20,5 (15,5–26).Efficacy data: After 3 months of treatment (n=37), the median number of migraine days was 5 (3-9). 13 (35%) of patients were non-responders, 10 (27%) were partial responders, and 14 (38%) were good responders.After 6 months (n=29), the median number of migraine days was 5 (3-9). The observed response rate was: 10 (34,5%) of patients were non-responders, 10 (34,5%) were partial responders, and 9 (31%) were good responders.Safety data: Adverse events were reported in 86,4% of patients. The most common were: 65,9% gastrointestinal symptoms (constipation and nausea); 43,2% central nervous system symptoms (fatigue, somnolence, and insomnia); 22,7% decreased appetite and 9,1% weight loss.7 (15,9%) patients discontinued treatment earlier due to intolerance.Conclusion and Relevance In our study, atogepant as a preventive treatment for patients with migraine significantly reduced the median number of monthly migraine days. At least two-thirds of the patients showed a clinical response, with a reduction greater than 50% achieved in one-third of them.A high percentage of patients reported adverse effects, leading to treatment discontinuation in 16% of cases.Conflict of Interest No conflict of interest